Bayer initiates OASIS 4 phase III study of elinzanetant in breast cancer patients with vasomotor symptoms caused by endocrine therapy

MLA

“Bayer Initiates OASIS 4 Phase III Study of Elinzanetant in Breast Cancer Patients with Vasomotor Symptoms Caused by Endocrine Therapy.” PharmaBiz, Oct. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.723049032&authtype=sso&custid=ns315887.

APA

Bayer initiates OASIS 4 phase III study of elinzanetant in breast cancer patients with vasomotor symptoms caused by endocrine therapy. (2022, October 18). PharmaBiz.

Chicago

PharmaBiz. 2022. “Bayer Initiates OASIS 4 Phase III Study of Elinzanetant in Breast Cancer Patients with Vasomotor Symptoms Caused by Endocrine Therapy,” October 18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.723049032&authtype=sso&custid=ns315887.